Most popular US graduate degrees aren’t worth the money, study shows: ‘A very risky proposition’

A study of ~800,000 students across three decades at Texas public universities finds graduate degrees in social work, psychology, and curriculum & instruction can yield zero to negative lifetime ROI after accounting for full cost. Medical doctorates nearly triple salaries and pharmacy doctorates raise earnings by over two-thirds, with law also among high-ROI programs; grad gains are larger for women, full-time students and those from lower-earning undergrad majors. Implication for portfolios: prospective students, particularly those using loans, face meaningful downside risk and should compare pre- and post-grad earnings before committing.

Analysis

The report is a demand shock disguised as information: clearer ROI data will accelerate rational substitution away from high-cost, low-return graduate programs over 1-3 years, not overnight. Expect enrollment reallocation toward shorter, employer-aligned credentials and away from credential paths with weak payoffs; a 10-20% secular decline in marginal grad enrollments is plausible within 24 months if schools don’t sharply discount tuition or repackage offers.

Second-order winners are low-cost, scalable delivery platforms and employer-paid upskilling channels that can capture price-sensitive adults; losers are program-level revenue pools at public universities and smaller niche grad departments whose fixed costs are high and whose redress options (cutting faculty or shuttering programs) carry political friction. Over 2-5 years this dynamic raises M&A and consolidation odds among education providers and increases counterparty risk for lenders with concentrated student-loan exposure to marginal graduate cohorts.

A parallel healthcare dynamic creates asymmetric opportunity: high-ROI clinical degrees keep supply growth constrained by training bottlenecks, supporting above-trend wage gains for clinicians and durable demand for staffing/telehealth intermediaries over 3-7 years. Policy catalysts — Dept. of Education disclosure rules or changes to income-driven repayment — can accelerate or reverse flows quickly (weeks–months), so position sizing and event hedges matter.

Key Decisions for Investors

• Long COUR (Coursera) — 12–24 month horizon. Buy a 1–2% NAV position as an asymmetric play on enterprise and individual credentialing growth; target +80–120% if market-share shifts accelerate. Stop-loss 30% — key risks are credential adoption rates and margin erosion from heavy content acquisition.
• Long UDMY (Udemy) — 12–18 month horizon. Allocate 0.5–1% NAV to capture direct-to-learner substitution away from expensive grad degrees. Reward: 50–100% if consumer/SMB uptake rises; Risk: 30% drawdown if macro consumer spending weakens.
• Long AMN (AMN Healthcare) — 6–18 month horizon. Buy 0.5–1% NAV to play persistent clinician wage inflation and staffing shortages driven by constrained physician/pharmacist pipeline. Target +30–50%, stop-loss 25%. Catalysts: rising utilization and contract pricing; risk: faster-than-expected pipeline expansion or reimbursement pressure.
• Pair trade — Long COUR / Short LOPE (Grand Canyon Education), equal dollar-weighted — 12–24 months. This isolates secular fee-for-service credentialing vs incumbent higher-ed capture. Risk/reward ~2:1 if employers accelerate credential recognition; macro/regulatory support for traditional providers could defeat the pair.